// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Prevalence and Predictors of Sleep Apnea in End Stage Renal Disease Patients on Home Nocturnal Hemodialysis

C. Lin - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

End stage renal disease

N/A

1 Antitrypsin Deficiency Using 3He and 129Xe MRI

A. V. Ouriadov - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Bronchodilator Is Associated with Dynamic Hyperinflation on Stage 1 Cardiopulmonary Exercise Testing in Patients with COPD

A. Kouri - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Dyspnea

N/A

World Cohort

I. Satia - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cholinergic Receptor Nicotinic Alpha 5 Expression in the Airways of Patients with Chronic Obstructive Pulmonary Disease

A. Tam - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Acting Beta Agonists on Bronchial Epithelium

N. Yang - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Olodaterol

Inspiratory Muscle Training on Respiratory Muscle Strength, Endurance and Functional Capacity in Obese Women

E. Pazzianotto-Forti - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The Effect of Thymol on Pseudomonas Aeruginosa Virulence Factors

Z. E. Suntres - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

lipase

Survival with Optimal Medical Management in a Cohort of Severe Necrotizing Bacterial Lung Infection

J. Larose - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Repeated Neonatal Oral Sucrose Treatment Affects Growth and Insulin-Like Growth Factor-1 in Mice

CYNTHIA YAMILKA RAMIREZ CONTRERAS - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

Mecasermin

PBI-4547 Orchestrates a Cross Talk between Liver and White Adipose Tissues to Correct Metabolic Reprogramming

JEAN-CHRISTOPHE SIMARD - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Human Pancreas-Derived Multipotent Stromal Cells Secrete Islet Regenerative Stimuli

TYLER COOPER - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hyperglycemia

N/A

Vitamin D Directly Regulates TRPV1 Channel Activity and May Play an Important Role in the Autoimmune Disease of Type 1 Diabetes

WENTONG LONG - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

Ergocalciferol

A Mendelian Randomization Study

MARIE PIGEYRE - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Angiotensin II

Incidence Trends of Diabetic Ketoacidosis at and after Diagnosis of Type 1 Diabetes in British Columbia, Canada

KUNG-TING KAO - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Diabetic ketoacidosis

N/A

Developing a Prognostic Model to Assess Dysglycemia Risk in Canadians Aged 18-39

SEBASTIAN A. SRUGO - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Artesunate Treatment Improves Hyperglycemia in a Rodent Model of Gestational Glucose Intolerance without Increasing Beta-Cell Mass

SANDRA SZLAPINSKI - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Prediabetes

artemisinin

Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME

BERNARD ZINMAN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

BI-10773

Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial

BERNARD CHARBONNEL - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Insulin glargine

Efficacy and Clinical Considerations of Flash Glucose Monitoring among Canadian Adults with Diabetes

ARIA JAZDAREHEE - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Copyright © 2026. QuantiNova All rights reserved